Weill Medical College of Cornell University

• Home
• Cancer and Blood Disorders
  • Solid Tumor
    • Bladder Cancer
    • Breast Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastric/Stomach Cancer
    • Head and Neck Cancer
    • Kidney/Renal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Ovarian/Peritoneal/Fallopian Tube Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Sarcoma
    • Soft Tissue Cancer

  • Multiple Myeloma
  • Leukemia and Myeloproliferative Disorders
    • Acute Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Chronic Myeloid Leukemia
    • Myelodysplastic Syndrome
    • Myelofibrosis
    • Polycythemia Vera

  • Lymphoma
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • Waldenstrom's Macroglobulinemia

  • Bone Marrow Transplant (BMT)
  • Benign Hematology
    • Anticoagulation
    • Bleeding and Platelet Disorders
• Cardiovascular/Heart
  • Aortic Aneurysms
  • Arrhythmias
  • Atrial Fibrillations
  • Coronary Artery Disease (CAD)
  • Inherited Heart Disease
  • Myocardial Infarction
  • Other Cardiovascular Diseases and Conditions
• Diabetes
• Gastrointestinal Diseases
  • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Hepatitis/HIV Co-Infection
  • Cancers of the Colon, Pancreas, Esophagus, Stomach
  • Celiac Disease
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Other Gastrointestinal Diseases
• Geriatrics
  • Pain and Palliative Care
• Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Hepatitis/HIV Co-infection
• Hypertension/High Blood Pressure
• HIV/AIDS and Infectious Diseases
• Kidney/Renal Disease
  • Kidney Transplants
• Lifestyle/Behavior Change
  • Medication Adherence
  • Hypertension Control
  • Colon Cancer Screening/Risk Reduction
• Pulmonary (Lung/Respiratory Tract) Disease
  • Asthma
  • Pneumonia
  • Pulmonary Fibrosis
  • Smokers
  • Other Respiratory/Lung Conditions
• Rheumatology Autoimmune Disease and Orthopedic Surgery
 
• Sleep Disorders
• Weight Loss/Obesity
• Healthy Volunteers

REO 017: A Phase 2 Study of Reolysin® in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Study Status

Closed to Enrollment

Study Description

The purpose of this study is to determine if combining REOLYSIN® with gemcitabine, the most common chemotherapy treatment, is effective in treating advanced or metastatic pancreatic cancer.

REOLYSIN® is a new form of cancer treatment that uses a type of virus called reovirus. This virus is commonly found in natural situations throughout the world (such as ponds and ditches) and may be associated with minor breathing or stomach upsets in humans.  Infection of cancer cells by this virus can slow cancer lesion growth and kill cancerous cells. The virus can cause a common cold in people but the virus is usually passed without causing harm.

The length of time you will be involved in this study will depend on how well you tolerate therapy with this treatment combination and how your disease responds. You can continue to receive the gemcitabine/REOLYSIN^® treatment if your disease has not progressed or worsened, or for as long as your study doctor and you feel that you are receiving benefit.  You will be followed one month after your last dose of the study treatment and then every three months, if possible, for as long as you are well and able to attend study visits.

Disease Status and/or Stage

Advanced or Metastatic Pancreatic Cancer

Key Eligibility

• Advanced or metastatic pancreatic cancer
• Have not received any prior chemotherapy or biotherapy
• Detailed eligibility reviewed when you contact the study team

Principal Investigator

Allyson Ocean, MD

Contact

• Gina Mileo, RN
• (212) 746-5430
• [email protected]